A circular RNA composition marker for distinguishing subtypes of non-small cell lung cancer and its application

Abstract

The present application discloses a circular RNA composition marker for diagnosing and identifying subtypes of non-small cell lung cancer and its application, including the application of hsa_circ_0069841, hsa_circ_001357 and the combination of hsa_circ_001357 and hsa_circ_0069841 in identifying non-small cell lung cancer subtypes, and also Provided are a kit and a gene chip made by detecting hsa_circ_0069841, hsa_circ_001357 and the reagents combined with hsa_circ_0069841. It is found in the present application that hsa_circ_0069841 and hsa_circ_001357, alone or in combination, have significant specificity and sensitivity for the identification of lung adenocarcinoma and lung squamous cell carcinoma in non-small cell lung cancer, and the diagnosis speed is fast, the cost is low, and the results are accurate and reliable. The kit and gene chip help to identify lung cancer subtypes quickly and accurately, and provide a reliable basis for targeted therapy for patients with non-small cell lung cancer.

Description

technical field [0001] The invention relates to the technical fields of medicine and clinical diagnosis, in particular to a circular RNA composition marker for identifying subtypes of non-small cell lung cancer and its application. Background technique [0002] Malignant tumors have become a major high-risk disease that seriously threatens human health. The morbidity and mortality of lung cancer rank first among all malignant tumors worldwide. [0003] Among lung cancers, non-small cell lung cancer (NSCLC) is the most common clinical pathological type of lung cancer, including squamous cell carcinoma (squamous cell carcinoma), adenocarcinoma, and large cell carcinoma. Compared with small cell carcinoma, its cancer cells grow and divide more slowly , the diffusion transfer is relatively late. It accounts for about 85% of the incidence of lung cancer. Limited by the lack of early screening methods with high specificity and sensitivity, about 75% of patients have local or di...

AI Technical Summary

Problems solved by technology

Limited by the lack of high-specificity and sensitivity early screening methods, about 75% of patients have local or distant metastases at the time of diagnosis. Due to the wide range of lesions, middle and advanced lung tumors are often difficult to be cured, and the 5-year survival rate is still insufficient 20%

[0006] In the prior art, the role of circular RNA in the diagnosis and treatment of lung cancer has also been proposed. For example, the Chinese patent No. 202010227453.3 "a circular RNA and its application" shows that by changing the expression of circular RNA circ_0058040 It has effects on the proliferation, apoptosis and drug sensitivity of non-small cell lung cancer cells, indicating that reducing the expression of circular RNA circ_0058040 can inhibit the proliferation of non-small cell lung cancer cells and enhance their sensitivity to targeted drugs, but it does not explain which gene Accurate detection of lung cancer biomarkers

The patent number is CN202010654555.3 "a diagnostic kit for detecting NSCLC and its use and application", although the hsa_circ_0069841 gene is given as a biomarker for detecting NSCLC, but there is no way to distinguish the specific type of lung cancer. Specifically for NSCLC, squamous cell carcinoma and adenocarcinoma have completely different histological sources, cell growth speed, speed of metastasis, and treatment methods. Therefore, for patients, there is still a lack of a fast and effective technical means. To determine whether a patient has squamous cell carcinoma or adenocarcinoma, so that doctors can better formulate treatment plans

Images